300171 Tofflon Science and Technology Group
WatchlistTofflon Science and Technology Group News
Dongfulong (300171): Under the influence of macro factors, the profit side is under pressure, and the fund-raising project is progressing smoothly
Event description: On October 27, 2023, the company released its report for the third quarter of 2023. 2023Q1-Q3 achieved operating income of 4.325 billion yuan, an increase of 13.31% over the previous year; achieved net profit
Hyde Control (002184.SZ): Major cooperative enterprises in the intelligent pharmaceutical equipment industry include Dongfulong, Chutian Technology, Zhejiang Tailin, and Xinhua Medical
On October 31, Gelonghui, Hyde Control (002184.SZ) stated on the investor interactive platform that the industrial informatization business, one of the company's main businesses, mainly provides safe and reliable automation, information product services, and automation and information technology integration system solutions for users in pharmaceutical and other industries. The company's main partners in the intelligent pharmaceutical equipment industry include Dongfulong, Chutian Technology, Zhejiang Tailin, and Xinhua Medical.
Dongfulong (300171): Actively developing customers and looking forward to order resumption
Event: October 26, 2023, the company released its 2023 three-quarter report. In the first three quarters of 2023, the company achieved operating income of 4.325 billion yuan, an increase of 13.31% over the previous year; net profit of 5.83
Dongfulong (300171.SZ) released results for the first three quarters, with net profit of 583 million yuan, a year-on-year decrease of 3.48%
Dongfulong (300171.SZ) released its report for the third quarter of 2023. The company achieved revenue of 43 in the first three quarters...
Dongfulong (300171): Revenue side growth is steady, pharmaceutical division and food division have impressive growth rates
The revenue side was steady, and gross margin declined year over year. In the first half of 2023, the company achieved revenue of 2,951 million yuan (+21.58% year on year), net profit attributable to mother of 426 million yuan (+5.82% year on year), after deducting net profit not attributable to parent 3
The upstarts at the “New Medicine King” ball
GLP-1, the “magic medicine for weight loss,” is a veritable “gold mine”, and behind it, China's two core industrial chains are actually hidden, and it is expected to become the biggest beneficiary of China's GLP-1 Dongfeng.
Dongfulong (300171.SZ): Appoints Lu Dehua's Chief Financial Officer
GLONGHUI, September 28, 丨 Dongfulong (300171.SZ) announced that the company held the fourth (interim) meeting of the 6th board of directors on September 28, 2023 to review and pass the “Bill on Appointing the Company's Financial Director”. According to the “Company Law of the People's Republic of China”, “Company Constitution” and other relevant regulations, after nomination and qualification review by the company board nomination committee, the audit committee reviewed and approved the appointment of Lu Dehua as the company's financial director. The term of office starts from the date of approval by the board of directors and ends at the end of the sixth board of directors.
Dongfulong (300171): Performance is growing steadily, and there is broad scope for domestic replacement of pharmaceutical equipment
Dongfulong announced the semi-annual announcement for 2023: in the first half of 2023, it achieved revenue of 2,951 billion yuan, an increase of 21.58% over the previous year; net profit of 426 million yuan, an increase of 5.82% over the previous year; net profit of non-attributable income was reduced
Dongfulong (300171) 2023 Interim Report Review: Injections Drive Steady Performance Growth and Continued Market Share Expansion
Dongfulong is a leading comprehensive pharmaceutical equipment service provider in China. In the short term, due to the phased downturn in the domestic and foreign biomedical investment and financing environment, the company's profitability is under pressure, but in the medium to long term, the company adheres to the “one, two wings” strategic plan, one
Gao Zhijian, financial director of Dongfulong (300171.SZ), resigns
Dongfulong (300171.SZ) announced that the company's board of directors recently received a written resignation report from financial director Gao Zhijian,...
Dongfulong (300171.SZ): In the first half of the year, it achieved revenue of 581 million yuan in overseas regions, accounting for 19.60% of revenue
GLONGHUI September 7 丨 Dongfulong (300171.SZ) held a performance briefing on September 7, 2023, on “Why is the company's overseas revenue declining? How are orders from overseas customers growing and expanding?” The company replied that in recent years, as competition in the international market has become more and more intense, trade frictions have been increasing. Faced with a complex and severe internal and external environment, the company actively strengthened domestic and foreign marketing efforts, actively participated in influential professional exhibitions and technical forums in the industry, stabilized and expanded market share, number of overseas customers and coverage regions, and demonstrated the excellent quality of Chinese pharmaceutical equipment on the international stage.
Tofulon (300171): Steady revenue growth in the first half of 2023
Incident: The company released its semi-annual report for 2023. During this period, it achieved operating income of 2.95 billion yuan, an increase of 21.6% over the previous year, and achieved net profit of 4.3 million yuan, an increase of 5.8% over the previous year. Of these, 2023Q2 achieved revenue of 15.3
Dongfulong (300171): Revenue side growth, steady gross margin fluctuations affect profit performance
Tofulong announced its 2023 annual report. In the first half of the year, we achieved operating income of 2,951 million yuan (up 21.58% year on year); realized net profit of 426 million yuan (up 5.82% year on year); achieved net profit after deducting net profit after deducting return to parent
Dongfulong (300171) 2023H1 review: The injectables business drove rapid growth in performance in the first half of the year
Event: On August 28, 2023, the company released its 2023 semi-annual report. In the first half of 2023, the company achieved operating income of 2,951 million yuan, an increase of 21.58% over the previous year; net profit of 426 million yuan
Dongfulong (300171.SZ) announced first-half results, net profit of 426 million yuan, an increase of 5.82%
According to Zhitong Financial App, Dongfulong (300171.SZ) released its 2023 semi-annual report. The company's revenue was 2,951 billion yuan, an increase of 21.58% over the previous year. Net profit attributable to shareholders of listed companies was 426 million yuan, an increase of 5.82% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 393 million yuan, an increase of 5.72% over the previous year. The basic earnings per share was 0.564 yuan.
Fulong Group, a shareholder of Societe Generale Yinxi (000426.SZ), has reduced its holdings by 0.55% for more than half of the time
According to the Zhitong Finance App, Societe Generale Yinxi (000426.SZ) issued an announcement. On July 17, 2023, the company received the “Notice from Chifeng Fulong Public Utility (Group) Co., Ltd. on the progress of implementation of the share reduction plan” from Fulong Group. Up to now, the holdings reduction period revealed in the above pre-disclosure announcement has been halfway through. Currently, it has reduced its holdings by 1.030,900 shares, a reduction ratio of 0.55%.
The 120 million restricted shares of Dongfulong (300171.SZ) will be listed for circulation on July 13
According to the Zhitong Finance App, Dongfulong (300171.SZ) announced that the number of restricted shares issued by the company to specific targets that have been lifted this time is 120 million shares, accounting for 15.7749% of the company's total share capital. The listing and circulation date is July 13, 2023 (Thursday).
Dongfulong (300171.SZ) plans to distribute $3.27753 for every 10 shares in 2022, excluding interest on June 29
According to the Zhitong Finance App, Dongfulong (300171.SZ) announced that the company plans to distribute a cash dividend of RMB 3.277,530 (tax included) for every 10 shares to all shareholders in 2022. There will be no transfer of share capital from the Capital Provident Fund, and no bonus shares. The registration date for this equity distribution is: 2023/6/28, and the expiry date is: 2023/6/29.
Dongfulong (300171): Revenue continues to grow steadily
Revenue growth has been steady, and the profit side is growing slower than the revenue side. In 2022, the company achieved revenue of 5.469 billion yuan (+30.46%), net profit of 847 million yuan (+2.27%), net profit of 780 million yuan (+2.56%), net profit of non-homo mother of 780 million yuan (+2.56%); 2022Q4 revenue of 1,652 million yuan (+26.12%), net profit of 242 million yuan (-10.20%), net profit of non-homo mother of 213 million yuan (-14.56%); 2023Q1 revenue of 1,423 million yuan (+14.99%), net profit of homo 2.31 million yuan
Dongfulong (300171.SZ): Net profit increased 9.26% to 231 million yuan in the first quarter
Gelonghui, April 26, 丨 Dongfulong (300171.SZ) announced its report for the first quarter of 2023. Revenue for the reporting period was 1,423 million yuan, up 14.99% year on year; net profit attributable to shareholders of listed companies was 231 million yuan, up 9.26% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 225 million yuan, up 13.85% year on year; basic earnings per share were 0.3058 yuan.